Insights Into Diffuse Large B-Cell Lymphoma (DLBCL) 2023
Perspectives on drivers in treatment decisions in the management of DLBCL, perception of various therapeutics, and understanding of the current and future treatment landscape
Faculty Chair
Christopher Flowers, MD
MD Anderson Cancer Center, Houston, TX, USA
Faculty Chair
John Burke, MD
Rocky Mountain Cancer Centers, Colorado Springs, CO, USA
Faculty Chair
Kami Maddocks, MD
The Ohio State University, Columbus, OH, USA
Faculty Chair
Kieron Dunleavy, MD
Medstar Georgetown University Hospital, Washington, DC, USA
Faculty Chair
Matthew Lunning, DO, FACP
University of Nebraska Medical Center, Omaha, NE, USA
More Information
- Dallas, TX
- Kansas, Oklahoma, Texas, Missouri, Arkansas, Louisiana
More Information
- Denver, CO
- Illinois, Iowa, Minnesota, Nebraska, North Dakota, South Dakota, Wisconsin, Michigan, Indiana, Ohio
More Information
- Chicago, IL
- Illinois, Iowa, Minnesota, Nebraska, North Dakota, South Dakota, Wisconsin, Michigan, Indiana, Ohio
More Information
- Philadelphia, PA
- Connecticut, Delaware, District of Columbia, Maine, Massachusetts, Maryland, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, Vermont
More Information
- Seattle, WA
- Northern California, Oregon, Washington, Idaho, Montana, Wyoming
REPORT SNAPSHOT
- A moderated roundtable discussion focusing on the treatment of DLBCL
- Disease state and data presentations are developed in conjunction with a national or regional oncology expert
- Insights on the following therapies will be obtained: rituximab, lenalidomide, obinutuzumab, idelalisib, bortezomib, ibrutinib, axicabtagene ciloleucel, polatuzumab vedotin
GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT
- Data collection is accomplished through use of audience response system questioning and moderated discussion
- The group of advisors comprises 10–15 medical oncologists representative of each region
